Current concepts. The malignant hyperthermia syndrome.
Nelson TE, Flewellen EH.
N Engl J Med. 1983 Aug 18;309(7):416-8. doi: 10.1056/NEJM198308183090706.
Malignant hyperthermia: a review.
Rosenberg H, Pollock N, Schiemann A, Bulger T, Stowell K.
Orphanet J Rare Dis. 2015 Aug 4;10:93. doi: 10.1186/s13023-015-0310-1.
Pathophysiology and Treatment of Malignant Hyperthermia.
Gregory H, Weant KA.
Adv Emerg Nurs J. 2021 Apr-Jun 01;43(2):102-110. doi: 10.1097/TME.0000000000000344.
What is malignant hyperthermia susceptibility?
Hopkins PM.
Br J Anaesth. 2023 Jul;131(1):5-8. doi: 10.1016/j.bja.2023.04.014. Epub 2023 May 15.
Hyperthermia and protein homeostasis: Cytoprotection and cell death.
Ahmed K, Zaidi SF, Mati-Ur-Rehman, Rehman R, Kondo T.
J Therm Biol. 2020 Jul;91:102615. doi: 10.1016/j.jtherbio.2020.102615. Epub 2020 May 8.
Malignant Hyperthermia.
Spruce L.
AORN J. 2020 Sep;112(3):281-290. doi: 10.1002/aorn.13167.
Malignant hyperthermia.
Bandschapp O, Girard T.
Swiss Med Wkly. 2012 Jul 31;142:w13652. doi: 10.4414/smw.2012.13652. eCollection 2012.
Malignant hyperthermia: still an issue for neuromuscular diseases?
De Wel B, Claeys KG.
Curr Opin Neurol. 2018 Oct;31(5):628-634. doi: 10.1097/WCO.0000000000000592.
Malignant Hyperthermia-Associated Rhabdomyolysis After Succinylcholine: A Case Report.
Otta JJ, Ohden L, Bell DG.
S D Med. 2021 Jan;74(1):17-20.
Malignant hyperthermia.
Sessler DI.
J Pediatr. 1986 Jul;109(1):9-14. doi: 10.1016/s0022-3476(86)80563-7.
